Entresto saves lives
June 28, 2016
Shortly to be funded in
Australia, angiotensin receptor
neprilysin inhibitor sacubitril/
valsartan was associated with
a reduction in cardiovascular
mortality, all-cause mortality, and
hospitalisations compared with
enalapril, according to a cost effective
analysis out of the UK,
Switzerland, Canada and the US
and published in JAMA Cardiology.
Eligible patients with heart failure
with reduced ejection fraction
will benefit most with extended
life and reduced hospitalisation,
both of which contribute to the
cost effectiveness of the drug
combination, researchers said.
Correct use of the product can
potentially lead to the prevention
of thousands of premature deaths
and hospitalisations for patients
with heart failure, authors said.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Jun 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Jun 16
